pISSN 2508-6235 eISSN 2508-7576

Table. 5.

Adverse events (AEs) of phentermine/topiramate

AuthorsNumber of subjectsDuration (months)Common AEsSerious AEsPsychiatric/cognitive AEs
Allison et al. (2012)34 (EQUIP)1,26713*ParesthesiaCholelithiasis (1)Insomnia (40, high dose)
*Dry mouthMyelogenous leukemia (1)Depression (24, high dose)
*ConstipationIrritability (23, high dose)
*DysgeusiaAnxiety (19, high dose)
*NasopharyngitisDisturbance in attention (18, high dose)
*Blurred vision (low dose, P=0.05)Jittery (7, high dose)
*Alopecia
*Hypoesthesia
*Dry eye
*Oral paresthesia
*Dry skin
*Anorexia
*Decreased serum bicarbonate
*Amenorrhea
*Aphasia
*Back injury
*Decreased serum potassium
*Parosmia
Gadde et al. (2011)35 (CONQUER)2,48713Dry mouthAnxiety (41, high dose)
ParesthesiaIrritability (34, high dose)
ConstipationDisturbance in attention (35, high dose)
Dysgeusia
Insomnia
Dizziness
Back pain
Nausea
Blurred vision
Garvey et al. (2012)4 (SEQUEL)67625 (extension of CONQUER)Paraesthesia
Nausea
Number in () means number of cases with the adverse events.

Occured at a rate of ≥1% in any treatment group and more frequently than in placebo group (P<0.05)

Occured at a rate of ≥5% in any treatment group and more frequently than in placebo group (P<0.05)

In the second year, paresthesia occurred more in high dose group and nausea occurred more in low dose group than in placebo group (P<0.05 by Fisher’s exact test)

Korean J Obes 2015;24:17~27 https://doi.org/10.7570/kjo.2015.24.1.17
© JOMES